Skip to content
karyopharm-logo
Logo for Karyopharm
Main Menu
Contact
Clinical Trials
Careers
Follow Us
LinkedIn
Twitter
Search
About
Show submenu
About Karyopharm
Management Team
Board of Directors
Scientific Advisory Board
Careers
Science
Show submenu
SINE Technology (Selective Inhibitor of Nuclear Export)
Pipeline
Our Medicines
Patients
Show submenu
Overview
SINE Technology
Multiple Myeloma
Diffuse Large B-Cell Lymphoma (DLBCL)
Clinical Trials
Patient Resources
Responsibility
Show submenu
Supporting Medical Research
Expanded Access
Grants & Giving
Corporate Sustainability
Investors & Media
Show submenu
Corporate Profile
Press Releases
Media Assets
Events & Presentations
Corporate Governance
Show submenu
Management Team
Board of Directors
Committee Composition
Contact the Board
Financial Information
SEC Filings
Annual Reports & Proxy Statements
Show submenu
SEC Filings
Annual Reports & Proxy Statements
Analyst Coverage
Investor FAQs
Publications and Presentations
Corporate Sustainability
Contact Us
Show submenu
Investor Alerts
Financial Information
> SEC Filings
NASDAQ
KPTI
Year
Trailing 12-Months
Calendar Year 2026
Calendar Year 2025
Calendar Year 2024
Calendar Year 2023
Calendar Year 2022
Calendar Year 2021
Calendar Year 2020
Calendar Year 2019
Calendar Year 2018
Calendar Year 2017
Calendar Year 2016
Calendar Year 2015
Calendar Year 2014
Calendar Year 2013
Calendar Year 2010
View
All Filings
Annual Filings
Quarterly Filings
Current Filings
Registration Statements
Section 16
Mergers & Acquisitions
Proxy & Information Statements
Other
Form
Description
Date
Format
424B4
Form of prospectus disclosing information facts events covered in both forms 424B1 424B3
Nov 7, 2013
Open Form of prospectus disclosing information facts events covered in both forms 424B1 424B3 in HTML.
Open Form of prospectus disclosing information facts events covered in both forms 424B1 424B3 in DOC file.
Open Form of prospectus disclosing information facts events covered in both forms 424B1 424B3 in PDF file.
Open Form of prospectus disclosing information facts events covered in both forms 424B1 424B3 in XLS file.
S-1MEF
Registration of up to an additional 20% of securities for any offering registered on an S-1
Nov 6, 2013
Open Registration of up to an additional 20% of securities for any offering registered on an S-1 in HTML.
Open Registration of up to an additional 20% of securities for any offering registered on an S-1 in DOC file.
Open Registration of up to an additional 20% of securities for any offering registered on an S-1 in PDF file.
Open Registration of up to an additional 20% of securities for any offering registered on an S-1 in XLS file.
8-A12B
Registration of certain classes of securities 12(b) of the Securities Exchange Act
Nov 1, 2013
Open Registration of certain classes of securities 12(b) of the Securities Exchange Act in HTML.
Open Registration of certain classes of securities 12(b) of the Securities Exchange Act in DOC file.
Open Registration of certain classes of securities 12(b) of the Securities Exchange Act in PDF file.
Open Registration of certain classes of securities 12(b) of the Securities Exchange Act in XLS file.
S-1/A
Amended Registration statement for face-amount certificate companies
Oct 28, 2013
Open Amended Registration statement for face-amount certificate companies in HTML.
Open Amended Registration statement for face-amount certificate companies in DOC file.
Open Amended Registration statement for face-amount certificate companies in PDF file.
Open Amended Registration statement for face-amount certificate companies in XLS file.
S-1
Registration statement for face-amount certificate companies
Oct 4, 2013
Open Registration statement for face-amount certificate companies in HTML.
Open Registration statement for face-amount certificate companies in DOC file.
Open Registration statement for face-amount certificate companies in PDF file.
Open Registration statement for face-amount certificate companies in XLS file.
Click here to print this page.
Click here to send us an email.
Agree to Our Terms of Use
I Agree
*
I agree to the storing and processing of my personal data by Karyopharm as described in the
Privacy Policy
and to the
Terms of Use
. I agree to receive communications from Karyopharm and understand that I can unsubscribe at any time.